| |
 |
Professor Pierce Chow, MBBS, MMed (Surg), FRCS, FAMS (Gen Surg), PhD
Senior Consultant Surgeon, Division of Surgical Oncology and Department of Hepatopancreatobiliary / Transplant Surgery, National Cancer Center Singapore and Singapore General Hospital
Professor, Duke-NUS Graduate Medical School
Singapore
|
|
| |
| Biography: |
|
| |
| Pierce Chow is an academic surgeon and Professor at the Duke-NUS Graduate Medical School. He is concurrently Senior Consultant Surgeon at the National Cancer Centre Singapore (NCCS) and the Singapore General Hospital (SGH), and NMRC Senior Clinician Scientist. He has published extensively on hepato-biliary cancers. Besides being actively involved in clinical trials on novel therapies, he leads collaborative research on the genomic heterogeneity of HCC and applications in precision medicine. He serves on academic, government and pharmaceutical advisory boards, and has more than 200 scientific publications. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 5 multi-national trials. He is currently the protocol chair of an investigator-initiated 26-center phase III trial of ytttriun-90 versus sorafenib in locally advanced HCC in the Asia-Pacific. In 2012, the National Medical Research Council Singapore conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer. |
| |
| Session: |
|
| |
| 20th November 2015 (Friday) |
 |
14:00 –14:30 |
|
| |
| Session I: Pre-clinical Oncology Research |
| The Development of BrachySil® – from Bench to First-in-Man |
| |
|
|
